On this page

AMAZON BASIC CARE LOPERAMIDE HYDROCHLORIDE

Loperamide Hydrochloride · Tablet

Over-the-counter ANDA Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
AMAZON BASIC CARE LOPERAMIDE HYDROCHLORIDE
Generic name
Loperamide Hydrochloride
Dosage form
Tablet
Route
Oral
Marketing category
ANDA · ANDA
Labeler
Amazon.com Services LLC
Product type
Human Otc Drug
DEA schedule
Not scheduled
Active ingredients
1
NDC product codes
2
Packages
2
Data completeness
76% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Loperamide Hydrochloride 2 mg/1 978006 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Tablet
Route of administration
Oral
Presentations
4

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Opioid Agonist [EPC] EPC All 109 members
Opioid Agonists [MoA] MoA All 35 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
206548
Application type
ANDA · Abbreviated New Drug Application
Approval date
December 15, 2015
Sponsor
AUROBINDO PHARMA
Products on application
1
Submissions recorded
6
Products approved under application 206548.
Product Trade name Form Strength Ingredient Status TE Flags
206548-001 LOPERAMIDE HYDROCHLORIDE TABLET LOPERAMIDE HYDROCHLORIDE Over-the-counter —

Approval history

Source: Drugs@FDA
Most recent submissions on application 206548.
Type No. Action Status Date Review
Supplement 11 Labeling Approved July 9, 2021 Standard
Supplement 8 Labeling Approved July 9, 2021 Standard
Supplement 6 Labeling Approved July 9, 2021 Standard
Supplement 3 Labeling Approved July 9, 2021 Standard
Supplement 1 Manufacturing (CMC) Approved May 28, 2019 —
Original application 1 Approved December 15, 2015 Standard

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260601). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN OTC DRUG · 20260601

Indications and Usage

openFDA Drug Labeling

Use controls symptoms of diarrhea, including Travelers' Diarrhea

Purpose Anti-diarrheal

Dosage and Administration

openFDA Drug Labeling

Directions • drink plenty of clear fluids to help prevent dehydration caused by diarrhea • find right dose on chart. If possible, use weight to dose; otherwise, use age. adults and children 12 years and over 2 tablets after the first loose stool; 1 tablet after each subsequent loose stool; but no more than 4 tablets in 24 hours children 9 to 11 years (60 to 95 lbs) 1 tablet after the first loose stool; 1/2 tablet after each subsequent loose stool; but no more than 3 tablets in 24 hours children 6 to 8 years (48 to 59 lbs) 1 tablet after the first loose stool; 1/2 tablet after each subsequent loose stool; but no more than 2 tablets in 24 hours children 2 to 5 years (34 to 47 lbs) ask a doctor children under 2 years (up to 33 lbs) do not use

Warnings Allergy alert: Do not use if you have ever had a rash or other allergic reaction to loperamide hydrochloride Heart alert: Taking more than directed can cause serious heart problems or death

Do not use if you have bloody or black stool

Ask a Doctor

openFDA Drug Labeling

Ask a doctor before use if you have • fever • mucus in the stool • a history of liver disease • a history of abnormal heart rhythm

Stop use and ask a doctor if • symptoms get worse • diarrhea lasts for more than 2 days • you get abdominal swelling or bulging. These may be signs of a serious condition.

Active Ingredient

openFDA Drug Labeling

Drug Facts Active ingredient (in each tablet) Loperamide hydrochloride USP 2 mg

Adverse event reports

Source: openFDA FAERS
50,038
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: LOPERAMIDE HYDROCHLORIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
72288-225-76 72288-225 Amazon.com Services LLC 4 BLISTER PACK in 1 CARTON (72288-225-76) / 6 TABLET in 1 BLISTER PACK May 15, 2024
82804-295-06 82804-295 Proficient Rx LP 1 BLISTER PACK in 1 CARTON (82804-295-06) / 6 TABLET in 1 BLISTER PACK June 5, 2026
72288-225 72288-225 Amazon.com Services LLC — May 15, 2024
82804-295 82804-295 Proficient Rx LP — May 15, 2024

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 10 sections on this page.